Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

 Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Shots:

  • The advancement of BI 456906 to P-II study is based on the safety and tolerability and a wt. loss in individuals with a BMI up to 40 kg/m2 , which will be a PBO controlled proof of concept study in patients with obesity and type 2 diabetes
  • BI in-licensed two candidates from Zealand for GLP-1/glucagon dual agonist, Zealand will receive ~$21M out of ~$399M milestones at the initiation of P-II study with royalties on sales. For long-acting amylin analog, Zealand to receive ~$309M milestones and royalties on sales
  • BI 456906 (qw) is dual-acting GLP-1/glucagon peptide, derived from the natural gut hormone oxyntomodulin activating both the GLP-1 and glucagon receptors and is a part of BI’s obesity and diabetes portfolio

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Multivu

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post